Synaptic Dysfunction in Depression: Potential Therapeutic Targets
Open accessThe DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index; 40 of the 54 sources its claims cite were checked for support.
Abstract
Basic and clinical studies demonstrate that depression is associated with reduced size of brain regions that regulate mood and cognition, including the prefrontal cortex and the hippocampus, and decreased neuronal synapses in these areas. Antidepressants can block or reverse these neuronal deficits, although typical antidepressants have limited efficacy and delayed response times of weeks to months. A notable recent discovery shows that ketamine, a N -methyl- d -aspartate receptor antagonist, produces rapid (within hours) antidepressant responses in patients who are resistant to typical antidepressants. Basic studies show that ketamine rapidly induces synaptogenesis and reverses the synaptic deficits caused by chronic stress. These findings highlight the central importance of homeostatic control of mood circuit connections and form the basis of a synaptogenic hypothesis of depression and treatment response.
Overview
CoChat Summary
TL;DR
The paper proposes a synaptogenic hypothesis of depression: stress and depression cause synaptic loss and neuronal atrophy in mood-related circuits, while rapid-acting ketamine reverses these deficits through glutamate burst, BDNF, mTOR, and synaptogenesis. It contrasts slow typical antidepressants with ketamine and highlights new therapeutic targets.
Key findings
- Depression is associated with decreased volume of cortical and limbic regions such as the prefrontal cortex (PFC) and hippocampus, and postmortem studies report decreased synapse number in the dorsolateral PFC, reduced pyramidal neuron size but not number, decreased GABAergic interneurons and glia, and altered GABA/glutamate cycling.
- Chronic stress in rodents reduces apical dendrite length and branching and decreases spine synapse number and function in layer V pyramidal neurons of the medial PFC; atrophy is observed after as little as 1 week of restraint stress (20 to 30 min per day), and chronic stress also decreases adult hippocampal neurogenesis and medial PFC glia.
- Ketamine produces rapid antidepressant responses within hours in treatment-resistant depressed patients, with effects sustained for 7 to 10 days; in rodents it rapidly induces synaptogenesis, reverses spine density deficits and anhedonia/anxiety caused by 3 weeks of chronic stress, and requires mTOR signaling, BDNF, Arc, and GSK3 inhibition.
- Typical antidepressants such as SSRIs take weeks to months to produce therapeutic response and leave more than one-third of depressed individuals resistant; they increase neurotrophic factor expression and plasticity slowly, whereas ketamine more profoundly affects fast excitatory glutamate transmission, BDNF release, and synaptogenesis.
Methods
- Review/perspective article synthesizing basic and clinical literature; no new primary data are reported.
- Evidence reviewed includes human brain-imaging and postmortem MDD studies, rodent chronic stress models (e.g., chronic unpredictable stress, restraint stress), and pharmacological studies of typical antidepressants and ketamine.
- Narrative synthesis comparing mechanisms of typical antidepressants and ketamine and proposing a synaptogenic hypothesis; no systematic review or meta-analysis is described.
Limitations
- Stated in the paper: MDD neurobiology remains poorly understood due to lack of biomarkers, relatively low heritability, and heterogeneity of precipitating factors; imaging provides connectivity information but not the integrity and efficiency of connections; postmortem neuronal morphology studies are hampered by poor fixation and tissue condition; preclinical interpretation is limited by available animal models, and additional human imaging is needed to confirm ketamine circuitry.
- Stated in the paper: ketamine’s psychotomimetic effects and abuse potential limit its development and use; clinical response to NR2B selective agents does not appear as rapid as ketamine, and further studies are needed; many molecular alterations in depression cannot always be distinguished from medication status because studies are not always sufficiently powered.
- Evident from the text: as a review, it does not provide a systematic search strategy, quality assessment, or primary quantitative synthesis; many mechanistic conclusions rely on rodent models and correlational human postmortem/imaging findings.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
27 Valid · 0 Not valid · 4 Not checked · 6 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Studies of neuronal morphology in human postmortem brain tissue have been hampered by poor fixation and tissue condition, but we recently reported that the number of synapses, determined by electron microscopy, is decreased in the dlPFC of depressed patients (16).”
§ Synaptic Dysfunction in Depression: Potential Therapeutic Targets > Neuronal Atrophy and Synaptic Loss in Depression
What the sources say
- Supportedcites [16] Kang HJ Nat. Med 2012 18 1413 22885997 PMC3491115 source
The paper reports a marked decrease in spine synapse number in the dorsolateral prefrontal cortex of subjects with major depressive disorder compared with controls. Its Electronic Microscopic Stereology methods describe counting those synapses in postmortem tissue using electron micrographs. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“A notable recent discovery shows that ketamine, a N-methyl-D-aspartate receptor antagonist, produces rapid (within hours) antidepressant responses in patients who are resistant to typical antidepressants.”
- Also stated in: § Abstract · boosted
“Recent studies report what is arguably the most important discovery in half a century: the therapeutic agent ketamine that produces rapid (within hours) antidepressant actions in treatment-resistant depressed patients (4, 5).”
§ Synaptic Dysfunction in Depression: Potential Therapeutic Targets > Abstract
What the sources say
- Not checked — no full text of the sourcecites [4] Berman RM Biol. Psychiatry 2000 47 351 10686270 source
- Supportedcites [5] Zarate CA Jr Arch. Gen. Psychiatry 2006 63 856 16894061 source
The Comment section reports a robust antidepressant response to ketamine within hours in treatment-resistant subjects, with improvement over placebo significant from 110 minutes on clinician ratings and 40 minutes on self-ratings. It also identifies ketamine as an NMDA antagonist. Page numbers are not provided in the supplied passages. (LLM, conf=0.94)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Abstract · boosted
Every source the paper cites for this claim was checked and supports it.
In the paper
“Chronic unpredictable stress (CUS), a putative model of depression, results in behavioral abnormalities, including core symptoms of depression such as anhedonia (7).”
§ Synaptic Dysfunction in Depression: Potential Therapeutic Targets > Stress Causes Neuronal Atrophy and Decreases Synaptic Density
What the sources say
- Supportedcites [7] Li N Biol. Psychol 2011 69 754 source
The Conclusions describe CUS as a paradigm that results in anhedonia, a core symptom of depression. The Results report that CUS-exposed rats showed reduced sucrose preference, indicating anhedonia, and increased latency to feed in a novel environment, indicating another behavioral abnormality. (LLM, conf=0.94)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“We have found that infusion of rapamycin into the medial PFC, but not the dorsal striatum, blocks the effects of systemic ketamine administration (6).”
§ Synaptic Dysfunction in Depression: Potential Therapeutic Targets > Rapid-Acting Antidepressants Increase Synaptogenesis
What the sources say
- Partly supportedcites [6] Li N Science 2010 329 959 20724638 PMC3116441 sourceExperimental — accuracy not yet measured
The passage on behavioral tests (labeled Abstract; Fig. 3D–F) reports that local rapamycin infusion into the medial PFC completely blocked ketamine’s effects in the forced swim and novelty-suppressed feeding tests. Our copy does not report a dorsal-striatum infusion or establish that it failed to block those effects, so the regional comparison is unsupported. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In addition, the synaptogenic actions of ketamine are blocked in mice with a knock-in of the BDNF Met allele that impairs BDNF mRNA transport to dendrites, as well as in conditional BDNF mutant mice (32, 49).”
§ Synaptic Dysfunction in Depression: Potential Therapeutic Targets > Rapid-Acting Antidepressants Increase Synaptogenesis
What the sources say
- Not matchedcites [32] Liu R Biol. Psychol 2012 71 996
Its entry has no title and year that we can search by.
- Partly supportedcites [49] Autry AE Nature 2011 475 91 21677641 PMC3172695 sourceExperimental — accuracy not yet measured
The Abstract (page not provided) reports that ketamine did not produce antidepressant-like behavioural effects in inducible BDNF knockout mice. It does not report that ketamine’s synaptogenic effects were blocked in those mice, or describe BDNF Met knock-in mice or impaired dendritic mRNA transport. (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Not matched
14 more claims · 10 with their cited sources checked
Create a free account to see all 37 claims and every source verdict.
- It may state two separate claims as one. 17
- Probably not a substantial claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While synaptic plasticity is a well-known key mechanism in learning and memory (Dayan and Cohen, 2011;Kandel, 2001), unequivocal studies suggest that dysfunction of synaptic plasticity with neuronal atrophy and cell death contribute to the pathophysiology of depression and therapeutic response could be associated with overcoming this deficit (Duman and Aghajanian, 2012;Krystal et al., 2013;Shakesb”
From Serotonin and neuroplasticity – Links between molecular, functional and structural pathophysiology in depression (2017) · cites this paper as Duman and Aghajanian, 2012
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, synaptic dysfunctions with neuronal atrophy and reductions of glial and GABAergic interneurons in the dorsolateral prefrontal cortex (dlPFC) are found in post-mortem analyses of brains of depressive patients (and animal models of chronic unpredictable stress; Duman and Aghajanian, 2012; Underwood et al., 2012).”
From Serotonin and neuroplasticity – Links between molecular, functional and structural pathophysiology in depression (2017) · cites this paper as Duman and Aghajanian, 2012
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Broadly, positive valence system deficits are linked primarily to altered dopaminergic and/or opioid signaling within midbrain striatal circuits 94,101 , but may intersect with plasticity impairments and dysconnectivity of excitatory glutamatergic synapses in an overlapping prefrontal-mesolimbic circuit 5 to produce the full spectrum of affective biases seen in depression.”
From Neuroplasticity in cognitive and psychological mechanisms of depression: an integrative model (2020) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Such complex effects seem to ultimately result in increased neurogenesis and synaptogenesis, improved neuroplasticity, and normalization of stress-related neurodegeneration [77,78].”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [77]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Postmortem findings from these animal models consistently demostrate that stress induces synaptic dysfunction [5,6,135], including reductions in synaptic density, as measured by both quantification of synaptic structure and assessments of synaptic protein expression”
From Challenges and rewards of in vivo synaptic density imaging, and its application to the study of depression (2025) · cites this paper as [6]
Experimental — accuracy not yet measured
16 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Kessler, R. C., Chiu, W. T., Demler, O., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.617 · Cited by 12,052
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Domingos da Silveira da Luz, A. C., Pereira Dias, G., do Nascimento Bevilaqua, M. C., Cocks, G., Gardino, P. F., Thuret, S., & Nardi, A. E. (2013) · Neuropsychobiology · doi:10.1159/000353269 · Cited by 3,995
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
The molecular neurobiology of depression
Krishnan, V., & Nestler, E. J. (2008) · Nature · doi:10.1038/nature07455 · Cited by 2,889
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881
Self-citationNMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926
Neurocircuitry of Mood Disorders
Price, J. L., & Drevets, W. C. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.104 · Cited by 1,606
Research works printed but not linked: 1
- 10.1016/j.pbb.2011.09.010 · DOI · Paper page
Cited by
Items 401–500 of 1,640
Corkery, J., Hung, W.-C., Claridge, H., Goodair, C., Copeland, C. S., & Schifano, F. (2021) · Journal of Psychopharmacology · doi:10.1177/02698811211021588 · Cited by 63
“Sub-anaesthetic doses (0.5 mg/kg for 40 min) have been used effectively in the treatment of individuals with treatment-resistant depression (TRD) (Duman and Aghajanian, 2012; George et al., 2017; Murrough et al., 2013) and treatment-resistant bipolar depression maintained on mood stabilisers (Diazgranados et al., 2010…”
MethodInfluentialMechanisms of action and clinical efficacy of NMDA receptor modulators in mood disorders
Ghasemi, M., Phillips, C., Fahimi, A., McNerney, M. W., & Salehi, A. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.07.002 · Cited by 100
Huang, Y.-L., Zeng, N.-X., Chen, J., Niu, J., Luo, W.-L., Liu, P., Yan, C., & Wu, L.-L. (2019) · Neural Regeneration Research · doi:10.4103/1673-5374.270414 · Cited by 50
“It also has been confirmed that the branch number and length of hippocampal neuron dendrites and their nerve regeneration ability are reduced, which indicates that abnormalities and dysfunctions of the hippocampus are strongly associated with depression (Duman and Aghajanian, 2012).”
BackgroundKohtala, S., Alitalo, O., Rosenholm, M., Rozov, S. V., & Rantamäki, T. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107741 · Cited by 50
Tian, L., Hui, C. W., Bisht, K., Tan, Y., Sharma, K. P., Chen, S., Zhang, X., & Tremblay, M. (2017) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.01.007 · Cited by 52
“…correlate of cognitive decline across a myriad of neurological disorders associated with chronic psychosocial stress, including depression, schizophrenia, and neurodegenerative diseases (Duman and Aghajanian, 2012; Jurgens et al., 2016; McEwen et al., 2015; Spires-Jones and Hyman, 2014).”
Price, J. B., Bronars, C., Erhardt, S., Cullen, K. R., Schwieler, L., Berk, M., Walder, K., McGee, S. L., Frye, M. A., & Tye, S. J. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.04.002 · Cited by 47
Oh, S.-J., Cheng, J., Jang, J., Arace, J., Jeong, M., Shin, C.-H., Park, J., Jin, J., Greengard, P., & Oh, Y. (2019) · Molecular Psychiatry · doi:10.1038/s41380-019-0384-6 · Cited by 51
Fernandes, M. Y. S. D., Dobrachinski, F., Silva, H. B. L., Lopes, J. P., Gonçalves, F. Q., Soares, F. A. A., Porciúncula, L. O., de Andrade, G. M., Cunha, R. A., & Tomé, Â. R. (2021) · Scientific Reports · doi:10.1038/s41598-021-89964-0 · Cited by 53
GABAA(δ) receptor hypofunction in the amygdala-hippocampal circuit underlies stress-induced anxiety
Qin, X., Pan, H., Huang, S.-H., Zou, J., Zheng, Z.-H., Liu, X., You, W.-J., Liu, Z.-P., Cao, J., Zhang, W.-H., et al. (2021) · 中国科学通报:英文版 · doi:10.1016/j.scib.2021.09.007 · Cited by 48
Lv, X., Lv, S., Wang, G., Chang, Y., Cai, Y., Liu, H.-Z., Xu, G.-Z., Xu, W., & Zhang, Y. (2024) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2024.01.012 · Cited by 50
Yi, B., Рыкова, М. П., Feuerecker, M., Jäger, B., Ladinig, C., Basner, M., Hoerl, M., Matzel, S., Kaufmann, I., Strewe, C., et al. (2014) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2014.03.018 · Cited by 58
Yang, S., Cheng, Y., Mo, Y., Bai, Y., Shen, Z., Liu, F., Li, N., Jiang, L., Chen, W., Lü, Y., et al. (2017) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2017.07.005 · Cited by 51
“Given the potential effect of antidepressants on neuronal plasticity (Arnone et al., 2013; Duman and Aghajanian, 2012), the small portion of the cases might have influenced the results to a limited extent.”
ResultLi, H., Qu, N., Hui, L., Cai, X. M., Zhang, C., Zhong, B., Zhang, S.-F., Chen, J., Xia, B., Wang, L., et al. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-0777-y · Cited by 46
Zuo, C., Cao, H., Ding, F., Zhao, J., Huang, Y., Guo, L., Huang, S., Jiang, H., Jiang, Y., & Wang, F. (2020) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2020.03.018 · Cited by 53
Rantamäki, T., & Kohtala, S. (2020) · Pharmacological Reviews · doi:10.1124/pr.119.018697 · Cited by 45
“…mitogen-activated protein kinase (MAPK) (Réus et al., 2014), mammalian target of rapamycin (mTOR) (Li et al., 2010), and glycogen synthase kinase 3b (GSK3b) (Beurel et al., 2011) (for reviews see Duman and Aghajanian, 2012; Duman et al., 2016; Rantamäki and Yalcin, 2016; Rantamäki, 2019) (Fig.”
BackgroundAstroglia in the Vulnerability to and Maintenance of Stress-Mediated Neuropathology and Depression
Miguel-Hidalgo, J. J. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.869779 · Cited by 56
“Since changes of synaptic plasticity are involved in the pathophysiology of stress responses, depression, and other psychiatric disorders (Duman and Aghajanian, 2012; Yuen et al., 2012; Treccani et al., 2014; Csabai et al., 2018), some researchers have targeted the putative involvement of astrocyte-expressed thrombosp…”
BackgroundComputer-Aided Recognition Based on Decision-Level Multimodal Fusion for Depression
Zhang, B., Cai, H., Song, Y., Tao, L., & Li, Y. (2022) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2022.3165640 · Cited by 54
“D EPRESSION is one of the most common mental disorders. thinking Its typical clinical symptoms are persistent sadness, slow , brain cognitive impairment, and lack of interest in things [1].”
BackgroundP2X2 receptors in pyramidal neurons are critical for regulating vulnerability to chronic stress
Kuang, X., Zhang, C.-Y., Yan, B.-Y., Cai, W.-Z., Lu, C., Xie, L.-J., Li, S.-J., Kong, P., Fan, J., Pan, S.-M., et al. (2022) · Theranostics · doi:10.7150/thno.72144 · Cited by 47
Wuwongse, S., Cheng, S. S., Wong, G. T.-H., Hung, C. H.-L., Zhang, N. Q., Ho, J. Y. S., Law, A. C.-K., & Chang, R. C. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.07.022 · Cited by 47
“They include alterations in brain-derived neurotrophic factor (BDNF) and disrupted synaptic signaling pathways responsible for synaptic maturation, impaired synaptic mitochondrial dynamics, and oxidative stress induced variations in synaptic genes [37] [38] [39].”
Background5HT3 receptors: Target for new antidepressant drugs
Gupta, D., Prabhakar, V., & Radhakrishnan, M. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.03.001 · Cited by 51
Makowska, I. J., & Weary, D. M. (2016) · PLoS ONE · doi:10.1371/journal.pone.0147595 · Cited by 50
Pasquali, M. A., Harlow, B. L., Soares, C. N., Otto, M. W., Cohen, L. S., Minuzzi, L., Gelain, D. P., Moreira, J. C. F., & Frey, B. N. (2018) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-017-0812-z · Cited by 39
“1 3 Current models propose that MDD is associated with alterations in neuronal plasticity, including deficits in neurotrophic factors [14, 48].”
BackgroundSchreurs, A., Sabanov, V., & Balschun, D. (2017) · Scientific Reports · doi:10.1038/s41598-017-05358-1 · Cited by 53
TrkB neurotrophin receptor at the core of antidepressant effects, but how?
Rantamäki, T. (2019) · Cell and Tissue Research · doi:10.1007/s00441-018-02985-6 · Cited by 45
Pan, J.-X., Deng, F.-L., Zeng, B., Zheng, P., Liang, W., Yin, B., Wu, J., Dong, M.-X., Luo, Y., Wang, H., et al. (2019) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2019.03.027 · Cited by 45
Patton, M. S., Lodge, D. J., Morilak, D. A., & Girotti, M. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.236 · Cited by 44
Nagy, C., Vaillancourt, K., & Turecki, G. (2018) · Genes, Brain and Behavior · doi:10.1111/gbb.12446 · Cited by 44
Fuxe, K., & Borroto-Escuela, D. O. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.1074175 · Cited by 43
“It is hypothesized that depression can be produced by loss of glutamate synaptic plasticity and even of glutamate synapses [21,22] in key circuits of mood and emotion.”
BackgroundPloski, J. E., & Vaidya, V. A. (2021) · Biological Psychiatry · doi:10.1016/j.biopsych.2021.04.009 · Cited by 51
Yang, J., Li, H., Hao, Z., Jing, X., Zhao, Y., Cheng, X., Ma, H., Wang, J., & Wang, J. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.1c18417 · Cited by 44
Neural plasticity and depression treatment
Wang, Y., Song, N., Ding, Y., & Zhang, L. (2022) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2022.09.001 · Cited by 55
“At cellular level, ketamine is able to prevent the reduction of spine density and impairment of synaptic functions in animal model of depression (Duman and Aghajanian, 2012).”
BackgroundGraham, B. M., Callaghan, B. L., & Richardson, R. (2014) · Behaviour Research and Therapy · doi:10.1016/j.brat.2014.07.012 · Cited by 43
“It is becoming increasingly recognised that in addition to modulating serotonin and norepinephrine, the therapeutic action of antidepressants may depend on their ability to influence a variety of messenger signals, transcription factors, and trophic factors in the brain (Duman & Aghajanian, 2012).”
BackgroundStress-protective neural circuits: not all roads lead through the prefrontal cortex
Christianson, J. P., & Greenwood, B. N. (2014) · Stress · doi:10.3109/10253890.2013.794450 · Cited by 43
Type 3 adenylyl cyclase: a key enzyme mediating the cAMP signaling in neuronal cilia.
Qiu, L., LeBel, R. P., Storm, D. R., & Chen, X. (2016) · Europe PMC (PubMed Central) · Cited by 55
Yan, C., Wu, L., Zeng, N.-X., Li, H., Wang, H., Liu, K., Gong, X., & Luo, W.-L. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.320993 · Cited by 48
“In addition, preclinical studies have demonstrated reduced numbers of branches, shorter hippocampal neuron dendrites, and impaired neurogenesis in animal models of depression (Danzer, 2012; Duman and Aghajanian, 2012).”
BackgroundMa, L., Wang, L., Chang, L., Shan, J., Qu, Y., Wang, X., Wan, X., Fujita, Y., & Hashimoto, K. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02192-6 · Cited by 45
“First, we performed RNA-sequencing analysis of PFC of CRS-exposed mice treated with either (R)-ketamine or saline, as PFC contributes to the antidepressant-like actions of ketamine and its enantiomers [52, 53].”
MethodMartín‐Hernández, D., Bris, Á. G., MacDowell, K. S., García‐Bueno, B., Madrigal, J. L. M., Leza, J. C., & Caso, J. R. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.11.029 · Cited by 47
The importance of epigenetics in diagnostics and treatment of major depressive disorder
Czarny, P., Białek, K., Ziółkowska, S., Strycharz, J., Barszczewska, G., & Sliwinski, T. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11030167 · Cited by 37
Maffioletti, E., Silva, R. C., Bortolomasi, M., Baune, B. T., Gennarelli, M., & Minelli, A. (2021) · Brain Sciences · doi:10.3390/brainsci11091120 · Cited by 45
Liaqat, H., Parveen, A., & Kim, S. Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314968 · Cited by 53
“In addition, the reduction in synaptic density and proteins (in response to depression) in the prefrontal cortexes of patients with depression is associated with the upregulation of a transcriptional repressor of synaptic proteins [32].”
BackgroundEngaging homeostatic plasticity to treat depression
Workman, E. R., Niere, F., & Raab‐Graham, K. F. (2017) · Molecular Psychiatry · doi:10.1038/mp.2017.225 · Cited by 47
Novel Pathways in the Treatment of Major Depression: Focus on the Glutamatergic System
Tomasetti, C., Montemitro, C., Fiengo, A. L. C., Santone, C., Orsolini, L., Valchera, A., Carano, A., Pompili, M., Serafini, G., Perna, G., et al. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190312102444 · Cited by 44
Qu, Y., Shan, J., Wang, S., Chang, L., Pu, Y., Wang, X., Tan, Y., Yamamoto, M. P., & Hashimoto, K. (2020) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-020-01208-w · Cited by 44
Huang, J., Shen, C., Ye, R., Shi, Y., & Li, W. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.539299 · Cited by 45
“Animal studies have found that neurons and glial atrophy are lost in the hippocampus of depression-likemodel animals (14).”
BackgroundMa, L., Wang, L., Chang, L., Shan, J., Qu, Y., Wang, X., Fujita, Y., & Hashimoto, K. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109250 · Cited by 45
Zhang, J., Yi, S., Li, Y., Xiao, C., Liu, C., Jiang, W., Yang, C., & Zhou, T. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05553-5 · Cited by 41
Baj, J., Bargieł, J., Cabaj, J., Skierkowski, B., Hunek, G., Portincasa, P., Flieger, J., & Smoleń, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242015071 · Cited by 53
“This finding instills optimism in individuals afflicted with geriatric depression as well as in the rest of the population.”
BackgroundPersistence of chronic major depression: A national prospective study
García-Toro, M., Rubio, J. M., Gili, M., Roca, M., Jin, C. J., Liu, S.-M., Bastianoni, C., & Blanco, C. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.06.013 · Cited by 50
“(Duman and Aghajanian, 2012; Garcia-Toro et al., 2012; Kocsis et al., 2008; de Maat et al., 2007) Our study also identified several risk factors for persistence.”
BackgroundGarner, R., Gopalakrishnan, S., McCauley, J. A., Bednar, R. A., Gaul, S. L., Mosser, S. D., Kiss, L., Lynch, J. J., Patel, S., Fandozzi, C., et al. (2015) · Pharmacology Research & Perspectives · doi:10.1002/prp2.198 · Cited by 41
Sun, X., Li, X., Pan, R., Xu, Y., Wang, Q., & Song, M. (2018) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-018-2186-9 · Cited by 42
“Recently, clinical and basic studies demonstrate that depression is associated with synaptic dysfunction in important regions such as prefrontal cortex and hippocampus [3].”
BackgroundMATHEUS, F. C., Rial, D., Real, J. I., Lemos, C., Takahashi, R. N., Bertoglio, L. J., Cunha, R. A., & Prediger, R. D. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9330-z · Cited by 50
“Also, PFC dysfunction underlies major depressive disorders [40, 47, 48] with preserved or disrupted hedonic function [49] and is also involved in the emergence of social phobia and their comorbidities [50].”
BackgroundQu, Y., Chang, L., Ma, L., Wan, X., & Hashimoto, K. (2022) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2022.173500 · Cited by 48
Pathophysiology of nAChRs: Limbic circuits and related disorders
Mineur, Y. S., Soares, A. R., Etherington, I. M., Abdulla, Z. I., & Picciotto, M. R. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106745 · Cited by 44
Greater subjective effects of a low dose of LSD in participants with depressed mood
Molla, H. M., Lee, R., Tare, I., & de Wit, H. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01772-4 · Cited by 48
Synaptic Abnormalities in the Infralimbic Cortex of a Model of Congenital Depression
Seese, R. R., Chen, L. Y., Cox, C. D., Schulz, D., Babayan, A. H., Bunney, W. E., Henn, F. A., Gall, C. M., & Lynch, G. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.2434-13.2013 · Cited by 40
“Similar effects are seen in cortex of chronically stressed rats (Duman and Aghajanian, 2012), but it is not known whether spine counts are decreased in cortical regions associated with depression.”
BackgroundZhang, J.-C., Yao, W., Qu, Y., Nakamura, M., Dong, C., Yang, C., Ren, Q., Ma, M., Han, M., Shirayama, Y., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-07325-2 · Cited by 50
The possible beneficial effects of creatine for the management of depression
Pazini, F. L., Cunha, M. P., & Rodrigues, A. L. S. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.08.029 · Cited by 40
“regions closely implicated in depressive symptoms (Duman and Aghajanian, 2012; Li et al., 2011; Pazini et al., 2016).”
Increasing Adiponergic System Activity as a Potential Treatment for Depressive Disorders
Formolo, D. A., Lee, T. H.-Y., & Yau, S. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-01644-3 · Cited by 42
Zhao, J., Liu, X., Chang, D., Zhang, X., Lian, H., Du, X., & Gao, L. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00669 · Cited by 40
Wu, L., Zhang, T., Chen, K., Lu, C., Liu, X. F., Zhou, J. L., Huang, Y., Yan, H., Chen, Y., Zhang, C. J., et al. (2020) · Phytotherapy Research · doi:10.1002/ptr.6812 · Cited by 43
Müller, W. E., Sillani, G., Schuwald, A. M., & Friedland, K. (2020) · Neurochemistry International · doi:10.1016/j.neuint.2020.104899 · Cited by 48
“Improvement of neuroplasticity seems to be the common final pathway of the mechanism of action of most if not all antidepressant drugs and occurs over the same time frame as the improvement of symptoms of depression and anxiety (Harmer et al., 2017; Serafini, 2012; Duman and Aghajanian, 2012; Duman and Duman, 2015; Ca…”
BackgroundDias, L., Lopes, C. R., Gonçalves, F. Q., Nunes, A. F., Pochmann, D., Machado, N. J., Tomé, Â. R., Agostinho, P. M., & Cunha, R. A. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.639322 · Cited by 44
“Since synaptic alterations have also been proposed to underlie stress-induced alterations of brain function (Duman and Aghajanian, 2012; Vose and Stanton, 2017), we also investigated if there was crosstalk between P2X7R and A2AR in synaptic alterations, namely in the process of LTP in the hippocampus.”
BackgroundThe Role of MeCP2 in Regulating Synaptic Plasticity in the Context of Stress and Depression
Sánchez-Lafuente, C. L., Kalynchuk, L. E., Caruncho, H. J., & Ausió, J. (2022) · Cells · doi:10.3390/cells11040748 · Cited by 45
Liebe, T., Li, M., Čolić, L., Munk, M. H. J., Sweeney‐Reed, C. M., Woelfer, M., Kretzschmar, M., Steiner, J., von Düring, F., Behnisch, G., et al. (2018) · NeuroImage Clinical · doi:10.1016/j.nicl.2018.09.001 · Cited by 48
Unno, K., Sumiyoshi, A., Konishi, T., Hayashi, M., Taguchi, K., Muguruma, Y., Inoue, K., Iguchi, K., Nonaka, H., Kawashima, R., et al. (2020) · Nutrients · doi:10.3390/nu12010174 · Cited by 39
“of the hippocampus, prefrontal cortex and amygdala [1,2].”
BackgroundNeurobiological aspects of suicide and suicide attempts in bipolar disorder
Mathews, D., Richards, E., Niciu, M., Ionescu, D., Rasimas, J., & Zarate, C. (2013) · Translational Neuroscience · doi:10.2478/s13380-013-0120-7 · Cited by 39
Shi, H., Wu, D., Chen, R., Li, N., & Zhu, L. (2022) · Theranostics · doi:10.7150/thno.70370 · Cited by 41
Val66Met polymorphism association with serum BDNF and inflammatory biomarkers in major depression
Caldieraro, M. A., McKee, M., Leistner-Segal, S., Vares, E. A., Kubaski, F., Spanemberg, L., Brusius-Facchin, A. C., Fleck, M. P., & Mischoulon, D. (2018) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2017.1347713 · Cited by 39
Zhang, K., He, M.-Y., Wang, F., Zhang, H., Li, Y., Yang, J., & Wu, C. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00834 · Cited by 38
Novel Targets to Treat Depression: Opioid-Based Therapeutics
Browne, C. A., Jacobson, M. L., & Lucki, I. (2020) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000242 · Cited by 40
Low‐Dose Copper Exposure Exacerbates Depression‐Like Behavior in ApoE4 Transgenic Mice
Xu, J., He, K., Zhang, K., Yang, C., Nie, L., Dan, D., Liu, J., Zhang, C.-E., & Yang, X. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/6634181 · Cited by 40
“Preclinical studies have also further reported low alterations of the density of synapses in depression models, especially in the prefrontal cortex and hippocampus [34, 37].”
Sala, N., Paoli, C., Bonifacino, T., Mingardi, J., Schiavon, E., Via, L. L., Milanese, M., Tornese, P., Datusalia, A. K., Rosa, J., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.759626 · Cited by 43
“A widely shared hypothesis suggests that abnormal enhancement of glutamate release/transmission induced by stress has a primary role in the neuroarchitecture changes observed (Duman and Aghajanian, 2012; Sanacora et al., 2012; Abdallah et al., 2015; McEwen et al., 2015; Musazzi et al., 2017a; Duman et al., 2019; Torne…”
BackgroundSingle-case experimental research designs.
Kazdin, A. E. (2015) · Methodological issues and strategies in clinical research (4th ed.). · doi:10.1037/14805-029 · Cited by 39
Khushboo, Siddiqi, N. J., Pereira, M. D. L., & Sharma, B. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-02780-z · Cited by 47
Fang, Q., Cai, H., Jiang, P., Zhao, H., Song, Y., Zhao, W., Yu, Y., & Zhu, J. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.01.051 · Cited by 39
Drinkenburg, W. H. I. M., Ahnaou, A., & Ruigt, G. S. F. (2015) · Neuropsychobiology · doi:10.1159/000443175 · Cited by 47
Synaptic alterations associated with depression and schizophrenia: potential as a therapeutic target
Calabrese, F., Riva, M. A., & Molteni, R. (2016) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2016.1188080 · Cited by 38
“Therefore, one intriguing possibility may involve a role for synaptic dysfunctions [6].”
BackgroundBortolozzi, A., Manashirov, S., Chen, A., & Artigas, F. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107873 · Cited by 37
Huang, J., Zhang, J., Zhang, T., Wang, P., & Zheng, Z. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.876136 · Cited by 41
Ma, T., Sun, Y., Wang, L., Wang, J., Wu, B., Yan, T., & Jia, Y. (2022) · Molecules · doi:10.3390/molecules27185809 · Cited by 42
“Many individuals are afflicted with depressive disorder (DD), a prevalent mental illness [13].”
BackgroundGlutamate Modulators in the Treatment of Obsessive-Compulsive Disorder
Pittenger, C. (2015) · Psychiatric Annals · doi:10.3928/00485713-20150602-06 · Cited by 37
Zhang, G.-F., Wang, N., Shi, J., Shixia, X., Li, X., Ji, M., Zuo, Z., Zhou, Z., & Yang, J. (2013) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2013.05.010 · Cited by 38
“Recent studies have shown that ketamine can rapidly increase synaptic proteins and the number and function of synaptic connections in the prefrontal cortex and reduce synaptic deficits to produce fast antidepressant effects in rodents (Duman and Aghajanian, 2012; Duman and Voleti, 2012).”
Lithium and GSK-3β promoter gene variants influence cortical gray matter volumes in bipolar disorder
Benedetti, F., Poletti, S., Radaelli, D., Locatelli, C., Pirovano, A., Lorenzi, C., Vai, B., Bollettini, I., Falini, A., Smeraldi, E., et al. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3770-4 · Cited by 39
“Both factors can favorably influence the loss of glial cells and the decrease of neuronal synapses which cause reduced GM volumes in BD (Duman and Aghajanian 2012).”
Kong, Y., Wang, T., Wang, R., Ma, Y., Song, S., Liu, J., Hu, W., & Li, S. (2017) · Science China Life Sciences · doi:10.1007/s11427-016-9034-8 · Cited by 42
Ni, X., Liao, Y., Li, L., Zhang, X., & Wu, Z. (2018) · Journal of Integrative Neuroscience · doi:10.31083/jin-170052 · Cited by 37
“Stress is a potent negative factor that can lead to psychiatric disease such as depression and anxiety disorders [1, 2].”
BackgroundThe effects of lobeline on nicotine withdrawal-induced depression-like behavior in mice
Roni, M. A., & Rahman, S. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3472-y · Cited by 39
Kotermanski, S. E., Johnson, J. W., & Thiels, E. (2013) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2013.05.005 · Cited by 46
“For instance, the NMDA receptor channel blocker ketamine shows great promise in the treatment of both pain (Prommer, 2012) and depression (Duman and Aghajanian, 2012).”
BackgroundVincenzo, M. D., Martiadis, V., Rocca, B. D., Arsenio, E., D’Arpa, A., Volpicelli, A., Luciano, M., Sampogna, G., & Fiorillo, A. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1394787 · Cited by 43
“…glutamate release stimulates the activation of AMPA receptors, by initiating intracellular signaling cascades, resulting in the activation of mammalian target of rapamycin (mTOR) and increase of brain-derived neurotrophic factor (BDNF) levels, with positive effects on synaptic plasticity (31, 32).”
BackgroundIn vitroandin vivoregulation of synaptogenesis by the novel antidepressant spadin
Devader, C., Khayachi, A., Veyssière, J., Maati, H. M. O., Roulot, M., Moréno, S., Borsotto, M., Martin, S., Heurteaux, C., & Mazella, J. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13083 · Cited by 41
“The recent discovery that ketamine, a non-competitive NMDA receptor antagonist, rapidly enhanced synaptogenesis and reversed synaptic deficits (Duman and Aghajanian, 2012), as well as the discovery of the peptide spadin which bears key properties of a potent antidepressant, may open new fields for treatment of mood di…”
BackgroundInfluentialNeurobiology of Rapid Acting Antidepressants: Role of BDNF and GSK-3β
Duman, R. S., & Aghajanian, G. K. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.217 · Cited by 41
Self-citationGlial mechanisms underlying major depressive disorder: Potential therapeutic opportunities
Rahman, S., & Alzarea, S. I. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.06.010 · Cited by 38
Li, W., Liu, X., & Qiao, H. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-0387-5 · Cited by 38
Popova, N. K., Ilchibaeva, T. V., Antonov, E. V., Pershina, A., Базовкина, Д. В., & Naumenko, V. S. (2020) · Alcohol · doi:10.1016/j.alcohol.2020.04.002 · Cited by 37
Maffioletti, E., Minelli, A., Tardito, D., & Gennarelli, M. (2020) · Genes · doi:10.3390/genes11091089 · Cited by 39
“These observations led to the development of a new research field aimed at developing both new molecules with neurotrophic action able to cross the blood-brain barrier to act directly on neurons, and molecules that can modulate the expression of genes encoding neurotrophic factors [32].”
BackgroundMa, L., Skoblenick, K., Seamans, J. K., & Everling, S. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.1839-15.2015 · Cited by 36
“Interestingly, recent studies have linked the increase in overall activity to the antidepressant effect of ketamine (Duman and Aghajanian, 2012; Fuchikami et al., 2015; Liu et al., 2015).”
BackgroundChen, X., Hou, X., Bai, D., Lane, R., Zhang, C., Canuso, C., Wang, G., & Fu, D.-J. (2023) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s391096 · Cited by 35
“Therefore, there is an unmet need for TRD intervention and novel treatments for the rapid relief of depressive symptoms.(12,13) Esketamine nasal spray (SPRAVATO), the rapidly acting S-enantiomer of ketamine, is approved in conjunction with an oral AD for the treatment of adults with TRD in the United States (US) and t…”
BackgroundEndocrine factors in key structural and intracellular changes in depression
Gold, P. W. (2021) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2021.01.003 · Cited by 35
A translational perspective on the anti-anhedonic effect of ketamine and its neural underpinnings
Pulcu, E., Guinea, C., Cowen, P. J., Murphy, S. E., & Harmer, C. J. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01183-1 · Cited by 35
Cheng, Y. G., Wang, X., Yu, Y., Gu, J., Zhao, M., Fu, Q., Song, Y., & Liu, Y. (2022) · Neurochemical Research · doi:10.1007/s11064-022-03683-0 · Cited by 36
“Synaptic deficits are evident in the neurobiology of depression [43, 44].”
BackgroundTong, Y. A., Zhao, G., Shuang, R., Wang, H., & Zeng, N. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.117289 · Cited by 43
Metadata
- Authors
- Duman, R. S., & Aghajanian, G. K.
- Affiliations
- Yale University (US)
- Corresponding author
- Duman, Ronald S.
- ORCID
- Duman, Ronald S.
- Venue
- Science
- Published
- 2012-10-05
- Volume
- 338
- Issue
- 6103
- Pages
- 68-72
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC4424898
- OpenAlex
- W2157504436
- Cited by
- 1,651
- References
- 57
- Citations by year
- 2026: 176 · 2025: 175 · 2024: 132 · 2023: 138 · 2022: 127 · 2021: 161 · 2020: 125 · 2019: 86 · 2018: 88 · 2017: 93 · 2016: 89 · 2015: 106 · 2014: 78 · 2013: 71 · 2012: 4
- FWCI
- 9.50
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Mental Health (R01MH093897)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- depression, synaptic dysfunction, synaptogenesis, ketamine, NMDA receptor antagonists, antidepressant resistance, chronic stress, prefrontal cortex, hippocampus, mood regulation, rapid antidepressant response, therapeutic target
- MeSH terms
- Animals, Antidepressive Agents, Atrophy, Behavior, Major Depressive Disorder, Homeostasis, Humans, Neurons, Stress, Psychological, Synapses, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.